The collaboration will initially focus on generating predictive data for patients with an undiagnosed immune dysfunction condition. Researchers at OMI will look to identify putative biomarkers and demonstrate how an integrated omics approach can improve sensitivity, accuracy and specificity of complex immune illness diagnosis, and potentially guide therapeutic decision making. The study will also use machine learning and additional big data analysis techniques to identify clinically relevant patterns of gene expression in single cells, as well as relationships between disparate-omic data types and single-cell expression patterns. Following the pilot project, the two organizations will explore a clinical laboratory developed test assay service that will be offered by the OMI CLIA laboratory.
“The 1CellBio inDrop System has shown to be a highly flexible, high-throughput scRNA-seq platform that provides enhanced experimental control and more actionable information compared to other existing platforms,” said Andreas Kogelnik, MD, PhD, Founder, The Open Medicine Institute. “This collaboration adds another dimension to our large-scale multi-omics data integration and clinical application practice, especially for the large number of our patients with undiagnosed immune dysfunction and inflammatory conditions, as well as other areas.”
